Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Other Accumulated Expenses: 2021-2025

Historic Other Accumulated Expenses for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $20.5 million.

  • Kiniksa Pharmaceuticals International's Other Accumulated Expenses rose 27.72% to $20.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.5 million, marking a year-over-year increase of 27.72%. This contributed to the annual value of $16.1 million for FY2024, which is 96.23% up from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Other Accumulated Expenses stood at $20.5 million for Q3 2025, which was up 14.01% from $18.0 million recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Other Accumulated Expenses peaked at $25.0 million during Q4 2021, and registered a low of $4.3 million during Q1 2023.
  • In the last 3 years, Kiniksa Pharmaceuticals International's Other Accumulated Expenses had a median value of $11.5 million in 2024 and averaged $12.7 million.
  • Per our database at Business Quant, Kiniksa Pharmaceuticals International's Other Accumulated Expenses tumbled by 80.49% in 2023 and then spiked by 163.66% in 2024.
  • Kiniksa Pharmaceuticals International's Other Accumulated Expenses (Quarterly) stood at $25.0 million in 2021, then crashed by 66.46% to $8.4 million in 2022, then fell by 2.21% to $8.2 million in 2023, then soared by 96.23% to $16.1 million in 2024, then rose by 27.72% to $20.5 million in 2025.
  • Its Other Accumulated Expenses stands at $20.5 million for Q3 2025, versus $18.0 million for Q2 2025 and $17.1 million for Q1 2025.